<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32203399</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Protein transmission in neurodegenerative disease.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>212</EndPage><MedlinePgn>199-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-020-0333-7</ELocationID><Abstract><AbstractText>Most neurodegenerative diseases are characterized by the intracellular or extracellular aggregation of misfolded proteins such as amyloid-&#x3b2; and tau in Alzheimer disease, &#x3b1;-synuclein in Parkinson disease, and TAR DNA-binding protein 43 in amyotrophic lateral sclerosis. Accumulating evidence from both human studies and disease models indicates that intercellular transmission and the subsequent templated amplification of these misfolded proteins are involved in the onset and progression of various neurodegenerative diseases. The misfolded proteins that are transferred between cells are referred to as 'pathological seeds'. Recent studies have made exciting progress in identifying the characteristics of different pathological seeds, particularly those isolated from diseased brains. Advances have also been made in our understanding of the molecular mechanisms that regulate the transmission process, and the influence of the host cell on the conformation and properties of pathological seeds. The aim of this Review is to summarize our current knowledge of the cell-to-cell transmission of pathological proteins and to identify key questions for future investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>The Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0003-3536-6902</Identifier><AffiliationInfo><Affiliation>The Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. vmylee@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043942" MajorTopicYN="N">Nanotubes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="Y">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32203399</ArticleId><ArticleId IdType="mid">NIHMS1685119</ArticleId><ArticleId IdType="pmc">PMC9242841</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-0333-7</ArticleId><ArticleId IdType="pii">10.1038/s41582-020-0333-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glenner GG &amp; Wong CW Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun 120, 885&#x2013;890 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL &amp; Selkoe DJ Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044&#x2013;4048 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M &amp; Goedert M -Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469&#x2013;6473 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990&#x2013;1993 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127, 299&#x2013;301 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253855</ArticleId><ArticleId IdType="pubmed">24362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna E et al. Differential &#x3b1;-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathol. 135, 855&#x2013;875 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5955788</ArticleId><ArticleId IdType="pubmed">29502200</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A et al. A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med 11, eaat8462 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci 22, 65&#x2013;77 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H et al. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol. Aging 24, 197&#x2013;211 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier DJ, Obeso JA &amp; Halliday GM Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci 18, 101&#x2013;113 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564322</ArticleId><ArticleId IdType="pubmed">28104909</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL &amp; Lee VM Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem 286, 15317&#x2013;15331 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J. Exp. Med 213, 2635&#x2013;2654 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949&#x2013;953 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA et al. Exogenous &#x3b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57&#x2013;71 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Del Tredici K Neuroanatomy and pathology of sporadic Parkinson&#x2019;s disease. Adv. Anat. Embryol. Cell Biol 201, 1&#x2013;119 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19230552</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H &amp; Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Del Tredici K The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol. 121, 171&#x2013;181 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M &amp; Braak H Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791&#x2013;1800 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR et al. Sequence of A&#x3b2;-protein deposition in the human medial temporal lobe. J. Neuropathol. Exp. Neurol 59, 733&#x2013;748 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC &amp; Gage FH Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918&#x2013;934 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL &amp; Lee VM Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med 20, 130&#x2013;138 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539&#x2013;1550 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL et al. Widespread tau seeding activity at early Braak stages. Acta Neuropathol. 133, 91&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833300</ArticleId><ArticleId IdType="pubmed">27878366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Del Tredici K, Thomas TL, Braak H &amp; Diamond MI Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol. 136, 57&#x2013;67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB &amp; Olanow CW Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat. Med 14, 504&#x2013;506 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat. Med 14, 501&#x2013;503 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z et al. Evidence for human transmission of amyloid-&#x3b2; pathology and cerebral amyloid angiopathy. Nature 525, 247&#x2013;250 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali I et al. Iatrogenic Creutzfeldt-Jakob disease with amyloid-&#x3b2; pathology: an international study. Acta Neuropathol. Commun 6, 5 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759292</ArticleId><ArticleId IdType="pubmed">29310723</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek K, Lutz MI, Aguzzi A, Kovacs GG &amp; Budka H Amyloid-&#x3b2; pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med. Wkly 146, w14287 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26812492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T et al. Significant association of cadaveric dura mater grafting with subpial A&#x3b2; deposition and meningeal amyloid angiopathy. Acta Neuropathol. 132, 313&#x2013;315 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27314593</ArticleId></ArticleIdList></Reference><Reference><Citation>Herve D et al. Fatal A&#x3b2; cerebral amyloid angiopathy 4 decades after a dural graft at the age of 2 years. Acta Neuropathol. 135, 801&#x2013;803 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29508058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie DL et al. Amyloid-&#x3b2; accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol. 134, 221&#x2013;240 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508038</ArticleId><ArticleId IdType="pubmed">28349199</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C et al. Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of A&#x3b2; pathology. Acta Neuropathol. 135, 201&#x2013;212 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29209767</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC et al. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J. Exp. Med 209, 975&#x2013;986 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225&#x2013;2228 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555&#x2013;19560 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M et al. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain 136, 1128&#x2013;1138 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C et al. Cellular milieu imparts distinct pathological &#x3b1;-synuclein strains in &#x3b1;-synucleinopathies. Nature 557, 558&#x2013;563 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970994</ArticleId><ArticleId IdType="pubmed">29743672</ArticleId></ArticleIdList></Reference><Reference><Citation>Recasens A et al. Lewy body extracts from Parkinson disease brains trigger &#x3b1;-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol 75, 351&#x2013;362 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24243558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimozawa A et al. Propagation of pathological &#x3b1;-synuclein in marmoset brain. Acta Neuropathol. Commun 5, 12 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289012</ArticleId><ArticleId IdType="pubmed">28148299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulusoy A et al. Caudo-rostral brain spreading of &#x3b1;-synuclein through vagal connections. EMBO Mol. Med 5, 1119&#x2013;1127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721477</ArticleId><ArticleId IdType="pubmed">23703938</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol 11, 909&#x2013;913 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeraer E et al. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis 73, 83&#x2013;95 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303592</ArticleId><ArticleId IdType="pubmed">25220759</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J. Neurosci 37, 11406&#x2013;11423 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep 2, 700 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. Elife 8, e43584 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Yetman MJ, Lillehaug S, Bjaalie JG, Leergaard TB &amp; Jankowsky JL Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct. Funct 221, 2231&#x2013;2249 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605847</ArticleId><ArticleId IdType="pubmed">25869275</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci 18, 1584&#x2013;1593 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD et al. Evidence for seeding of &#x3b2;-amyloid by intracerebral infusion of Alzheimer brain extracts in &#x3b2;-amyloid precursor protein-transgenic mice. J. Neurosci 20, 3606&#x2013;3611 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science 313, 1781&#x2013;1784 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohr J et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proc. Natl Acad. Sci. USA 109, 11025&#x2013;11030 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, O&#x2019;Brien J &amp; Bertolotti A Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl Acad. Sci. USA 108, 3548&#x2013;3553 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048161</ArticleId><ArticleId IdType="pubmed">21321227</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekooki-Machida Y et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl Acad. Sci. USA 106, 9679&#x2013;9684 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689308</ArticleId><ArticleId IdType="pubmed">19487684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren PH et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol 11, 219&#x2013;225 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757079</ArticleId><ArticleId IdType="pubmed">19151706</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc 132, 1186&#x2013;1187 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun 9, 4220 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Takahashi H, Ohama E &amp; Ikuta F Parkinson&#x2019;s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79, 581&#x2013;583 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">1972853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Takahashi H, Takeda S, Ohama E &amp; Ikuta F Parkinson&#x2019;s disease: the presence of Lewy bodies in Auerbach&#x2019;s and Meissner&#x2019;s plexuses. Acta Neuropathol. 76, 217&#x2013;221 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2850698</ArticleId></ArticleIdList></Reference><Reference><Citation>Killinger BA et al. The vermiform appendix impacts the risk of developing Parkinson&#x2019;s disease. Sci. Transl. Med 10, eaar5280 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319259</ArticleId><ArticleId IdType="pubmed">30381408</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Tredici K, Hawkes CH, Ghebremedhin E &amp; Braak H Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson&#x2019;s disease. Acta Neuropathol. 119, 703&#x2013;713 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20229352</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E et al. Vagotomy and subsequent risk of Parkinson&#x2019;s disease. Ann. Neurol 78, 522&#x2013;529 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26031848</ArticleId></ArticleIdList></Reference><Reference><Citation>Breid S et al. Neuroinvasion of &#x3b1;-synuclein prionoids after intraperitoneal and intraglossal inoculation. J. Virol 90, 9182&#x2013;9193 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5044858</ArticleId><ArticleId IdType="pubmed">27489279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl Acad. Sci. USA 111, 10732&#x2013;10737 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115570</ArticleId><ArticleId IdType="pubmed">25002524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI et al. Robust central nervous system pathology in transgenic mice following peripheral injection of &#x3b1;-synuclein fibrils. J. Virol 91, e02095&#x2013;16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215322</ArticleId><ArticleId IdType="pubmed">27852849</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura N et al. Inoculation of &#x3b1;-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol. Neurodegener 13, 21 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948849</ArticleId><ArticleId IdType="pubmed">29751824</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QX et al. Proteolytic processing of Alzheimer&#x2019;s disease beta A4 amyloid precursor protein in human platelets. J. Biol. Chem 270, 14140&#x2013;14147 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7775475</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Zhu A, Holsinger RM, Masters CL &amp; Li QX Proteolytic processing of the Alzheimer&#x2019;s disease amyloid precursor protein in brain and platelets. J. Neurosci. Res 74, 386&#x2013;392 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14598315</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl Acad. Sci. USA 91, 11993&#x2013;11997 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM et al. Elevated A&#x3b2;42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of A&#x3b2;PP metabolism. Am. J. Pathol 156, 797&#x2013;805 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876838</ArticleId><ArticleId IdType="pubmed">10702395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer&#x2019;s amyloid beta. Biochem. Biophys. Res. Commun 205, 1431&#x2013;1437 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7802679</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R &amp; Zlokovic BV Role of the blood-brain barrier in the pathogenesis of Alzheimer&#x2019;s disease. Curr. Alzheimer Res 4, 191&#x2013;197 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17430246</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS et al. Induction of cerebral &#x3b2;-amyloidosis: intracerebral versus systemic A&#x3b2; inoculation. Proc. Natl Acad. Sci. USA 106, 12926&#x2013;12931 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS et al. Peripherally applied A&#x3b2;-containing inoculates induce cerebral &#x3b2;-amyloidosis. Science 330, 980&#x2013;982 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL et al. Blood-derived amyloid-&#x3b2; protein induces Alzheimer&#x2019;s disease pathologies. Mol. Psychiatry 23, 1948&#x2013;1956 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29086767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem 288, 1856&#x2013;1870 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahic M, Bousset L, Bieri G, Melki R &amp; Gitler AD Axonal transport and secretion of fibrillar forms of &#x3b1;-synuclein, A&#x3b2;42 peptide and HTTExon 1. Acta Neuropathol. 131, 539&#x2013;548 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789229</ArticleId><ArticleId IdType="pubmed">26820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Freundt EC et al. Neuron-to-neuron transmission of &#x3b1;-synuclein fibrils through axonal transport. Ann. Neurol 72, 517&#x2013;524 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490229</ArticleId><ArticleId IdType="pubmed">23109146</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM et al. Detection of oligomeric forms of &#x3b1;-synuclein protein in human plasma as a potential biomarker for Parkinson&#x2019;s disease. FASEB J. 20, 419&#x2013;425 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16507759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B et al. Direct quantification of CSF &#x3b1;-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol 213, 315&#x2013;325 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18625222</ArticleId></ArticleIdList></Reference><Reference><Citation>Buch K et al. Tau protein. A potential biological indicator for early detection of Alzheimer disease [German]. Nervenarzt 69, 379&#x2013;385 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9629553</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci 31, 13110&#x2013;13117 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E et al. Cell-produced &#x3b1;-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci 30, 6838&#x2013;6851 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L et al. Lysosomal dysfunction increases exosome-mediated &#x3b1;-synuclein release and transmission. Neurobiol. Dis 42, 360&#x2013;367 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107939</ArticleId><ArticleId IdType="pubmed">21303699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M et al. Plasma exosomal &#x3b1;-synuclein is likely CNS-derived and increased in Parkinson&#x2019;s disease. Acta Neuropathol. 128, 639&#x2013;650 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201967</ArticleId><ArticleId IdType="pubmed">24997849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunadt M et al. Extracellular vesicle sorting of &#x3b1;-synuclein is regulated by sumoylation. Acta Neuropathol. 129, 695&#x2013;713 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405286</ArticleId><ArticleId IdType="pubmed">25778619</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM et al. Exosomal cell-to-cell transmission of &#x3b1; synuclein oligomers. Mol. Neurodegener 7, 42 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483256</ArticleId><ArticleId IdType="pubmed">22920859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong SM et al. Parkinson&#x2019;s disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes &#x3b1;-synuclein externalization via exosomes. Hum. Mol. Genet 23, 2816&#x2013;2833 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24603074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T, Hamada K &amp; Krainc D ATP13A2/PARK9 regulates secretion of exosomes and &#x3b1;-synuclein. J. Neurosci 34, 15281&#x2013;15287 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228131</ArticleId><ArticleId IdType="pubmed">25392495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan-Montojo F et al. Environmental toxins trigger PD-like progression via increased &#x3b1;-synuclein release from enteric neurons in mice. Sci. Rep 2, 898 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510466</ArticleId><ArticleId IdType="pubmed">23205266</ArticleId></ArticleIdList></Reference><Reference><Citation>Poehler AM et al. Autophagy modulates SNCA/&#x3b1;-synuclein release, thereby generating a hostile microenvironment. Autophagy 10, 2171&#x2013;2192 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502760</ArticleId><ArticleId IdType="pubmed">25484190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngolab J et al. Brain-derived exosomes from dementia with Lewy bodies propagate &#x3b1;-synuclein pathology. Acta Neuropathol. Commun 5, 46 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466770</ArticleId><ArticleId IdType="pubmed">28599681</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem 287, 3842&#x2013;3849 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener 12, 5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingtdeux V et al. Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J. Biol. Chem 282, 18197&#x2013;18205 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17468104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharples RA et al. Inhibition of &#x3b3;-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 22, 1469&#x2013;1478 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18171695</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Gonzalez R, Gauthier SA, Kumar A &amp; Levy E The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J. Biol. Chem 287, 43108&#x2013;43115 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522305</ArticleId><ArticleId IdType="pubmed">23129776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca MS et al. Identification of preclinical Alzheimer&#x2019;s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 11, 600&#x2013;607.e1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329112</ArticleId><ArticleId IdType="pubmed">25130657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkins MB, Dasgupta S, Wang G, Zhu G &amp; Bieberich E Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 35, 1792&#x2013;1800 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035236</ArticleId><ArticleId IdType="pubmed">24650793</ArticleId></ArticleIdList></Reference><Reference><Citation>An K et al. Exosomes neutralize synaptic-plasticity-disrupting activity of A&#x3b2; assemblies in vivo. Mol. Brain 6, 47 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222117</ArticleId><ArticleId IdType="pubmed">24284042</ArticleId></ArticleIdList></Reference><Reference><Citation>Melachroinou K et al. Deregulation of calcium homeostasis mediates secreted &#x3b1;-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853&#x2013;2865 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23891486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejlerskov P et al. Tubulin polymerization-promoting protein (TPPP/p25&#x3b1;) promotes unconventional secretion of &#x3b1;-synuclein through exophagy by impairing autophagosome-lysosome fusion. J. Biol. Chem 288, 17313&#x2013;17335 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682534</ArticleId><ArticleId IdType="pubmed">23629650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL &amp; Citron M Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis 48, 356&#x2013;366 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM &amp; Diamond MI Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem 287, 19440&#x2013;19451 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T et al. Unconventional secretion mediates the trans-cellular spreading of Tau. Cell Rep. 23, 2039&#x2013;2055 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One 9, e100760 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074092</ArticleId><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem 279, 20296&#x2013;20306 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC et al. A&#x3b2; is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci 7, 954&#x2013;960 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl Acad. Sci. USA 96, 14088&#x2013;14093 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO et al. Cerebral amyloid angiopathy: amyloid &#x3b2; accumulates in putative interstitial fluid drainage pathways in Alzheimer&#x2019;s disease. Am. J. Pathol 153, 725&#x2013;733 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138&#x2013;E3147 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Holmes BB, Sanders DW, Bieschke J &amp; Diamond MI Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J. Biol. Chem 290, 14893&#x2013;14903 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpowicz RJ Jr. et al. Selective imaging of internalized proteopathic &#x3b1;-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. J. Biol. Chem 292, 13482&#x2013;13497 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555207</ArticleId><ArticleId IdType="pubmed">28611062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ et al. Assembly-dependent endocytosis and clearance of extracellular &#x3b1;-synuclein. Int. J. Biochem. Cell Biol 40, 1835&#x2013;1849 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18291704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X et al. Pathological &#x3b1;-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510615</ArticleId><ArticleId IdType="pubmed">27708076</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavin WP et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 134, 629&#x2013;653 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28527044</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P &amp; Moechars D Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931&#x2013;940 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Noad J, McMahon H, Randow F &amp; Goedert M Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J. Biol. Chem 293, 2438&#x2013;2451 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818177</ArticleId><ArticleId IdType="pubmed">29282296</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo M et al. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J. Cell Sci 126, 3678&#x2013;3685 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23781027</ArticleId></ArticleIdList></Reference><Reference><Citation>Abounit S, Wu JW, Duff K, Victoria GS &amp; Zurzolo C Tunneling nanotubes: a possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. Prion 10, 344&#x2013;351 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5105909</ArticleId><ArticleId IdType="pubmed">27715442</ArticleId></ArticleIdList></Reference><Reference><Citation>Abounit S et al. Tunneling nanotubes spread fibrillar &#x3b1;-synuclein by intercellular trafficking of lysosomes. EMBO J. 35, 2120&#x2013;2138 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048354</ArticleId><ArticleId IdType="pubmed">27550960</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami J et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J. Neurosci 37, 11835&#x2013;11853 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719970</ArticleId><ArticleId IdType="pubmed">29089438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieriks BV et al. &#x3b1;-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson&#x2019;s disease patients. Sci. Rep 7, 42984 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322400</ArticleId><ArticleId IdType="pubmed">28230073</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F et al. Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. J. Neurosci 31, 14488&#x2013;14495 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschi SK et al. Highly potent soluble amyloid-&#x3b2; seeds in human Alzheimer brain but not cerebrospinal fluid. Brain 137, 2909&#x2013;2915 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5367518</ArticleId><ArticleId IdType="pubmed">25212850</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzesco AM et al. Highly potent intracellular membrane-associated A&#x3b2; seeds. Sci. Rep 6, 28125 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911570</ArticleId><ArticleId IdType="pubmed">27311744</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat. Commun 6, 8490 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ et al. Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human P301S Tau. J. Neurosci 36, 762&#x2013;772 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H et al. Inert and seed-competent tau monomers suggest structural origins of aggregation. Elife 7, e36584 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039173</ArticleId><ArticleId IdType="pubmed">29988016</ArticleId></ArticleIdList></Reference><Reference><Citation>Polinski NK et al. Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson&#x2019;s disease in rodents. J. Parkinsons Dis 8, 303&#x2013;322 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004926</ArticleId><ArticleId IdType="pubmed">29400668</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Krebs SK, Wolff M, Birk G &amp; Hengerer B Seeding induced by alpha-synuclein oligomers provides evidence for spreading of &#x3b1;-synuclein pathology. J. Neurochem 111, 192&#x2013;203 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19686384</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM et al. Different species of &#x3b1;-synuclein oligomers induce calcium influx and seeding. J. Neurosci 27, 9220&#x2013;9232 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672196</ArticleId><ArticleId IdType="pubmed">17715357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri L, Madiona K &amp; Melki R Structural and functional properties of prefibrillar &#x3b1;-synuclein oligomers. Sci. Rep 6, 24526 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830946</ArticleId><ArticleId IdType="pubmed">27075649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerqvist T et al. Off-pathway alpha-synuclein oligomers seem to alter alpha-synuclein turnover in a cell model but lack seeding capability in vivo. Amyloid 20, 233&#x2013;244 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24053224</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103&#x2013;117 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousset L et al. Structural and functional characterization of two &#x3b1;-synuclein strains. Nat. Commun 4, 2575 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826637</ArticleId><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W et al. &#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340&#x2013;344 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB et al. Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl Acad. Sci. USA 112, E5308&#x2013;E5317 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL et al. Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl Acad. Sci. USA 112, E4949&#x2013;E4958 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568231</ArticleId><ArticleId IdType="pubmed">26286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell 154, 1257&#x2013;1268 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner G et al. Seeded strain-like transmission of &#x3b2;-amyloid morphotypes in APP transgenic mice. EMBO Rep. 14, 1017&#x2013;1022 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818077</ArticleId><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT et al. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Science 307, 262&#x2013;265 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC et al. Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer&#x2019;s disease patients. Proc. Natl Acad. Sci. USA 111, 10323&#x2013;10328 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer&#x2019;s disease or corticobasal degeneration brains. Acta Neuropathol. 129, 221&#x2013;237 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Yamanaka K &amp; Nukina N Mutation-dependent polymorphism of Cu,Zn-superoxide dismutase aggregates in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem 285, 22221&#x2013;22231 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903422</ArticleId><ArticleId IdType="pubmed">20404329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Heikenwalder M &amp; Polymenidou M Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol 8, 552&#x2013;561 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17585315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JW Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol 6, 11&#x2013;17 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8696966</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM Protein misfolding, evolution and disease. Trends Biochem. Sci 24, 329&#x2013;332 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10470028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding F, LaRocque JJ &amp; Dokholyan NV Direct observation of protein folding, aggregation, and a prion-like conformational conversion. J. Biol. Chem 280, 40235&#x2013;40240 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16204250</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare SD, Caplow M &amp; Dokholyan NV The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 101, 15094&#x2013;15099 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524068</ArticleId><ArticleId IdType="pubmed">15475574</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y &amp; Hansmann UH Helix versus sheet formation in a small peptide. Phys. Rev. E Stat. Nonlin. Soft Matter Phys 68, 041911 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14682977</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler RL &amp; Dokholyan NV The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog. Mol. Biol. Transl. Sci 107, 215&#x2013;262 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605887</ArticleId><ArticleId IdType="pubmed">22482452</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL et al. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat. Struct. Mol. Biol 25, 463&#x2013;471 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakhamia T et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180, 633&#x2013;644.e12 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491959</ArticleId><ArticleId IdType="pubmed">32032505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Novel tau filament fold in corticobasal degeneration. Nature 10.1038/s41586-020-2043-0 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2043-0</ArticleId><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope TE et al. Tau burden and the functional connectome in Alzheimer&#x2019;s disease and progressive supranuclear palsy. Brain 141, 550&#x2013;567 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K &amp; Iwatsubo T Extracellular alpha-synuclein levels are regulated by neuronal activity. Mol. Neurodegener 13, 9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822605</ArticleId><ArticleId IdType="pubmed">29467003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci 19, 1085&#x2013;1092 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med 211, 387&#x2013;393 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz MK Jr. et al. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice. Neurobiol. Dis 118, 161&#x2013;176 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30049665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W &amp; Hanger DP Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389&#x2013;394 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880&#x2013;884 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed NV, Desjardins A &amp; Leclerc N Tau secretion is correlated to an increase of Golgi dynamics. PLoS One 12, e0178288 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446162</ArticleId><ArticleId IdType="pubmed">28552936</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep 5, 11161 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Seo BR &amp; Koh JY Metallothionein-3 modulates the amyloid beta endocytosis of astrocytes through its effects on actin polymerization. Mol. Brain 8, 84 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670512</ArticleId><ArticleId IdType="pubmed">26637294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolos M et al. Direct evidence of internalization of tau by microglia in vitro and in vivo. J. Alzheimers Dis 50, 77&#x2013;87 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26638867</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini-Stoica H et al. TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J. Exp. Med 215, 2355&#x2013;2377 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122971</ArticleId><ArticleId IdType="pubmed">30108137</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P et al. Matrix metalloproteinase-9 degrades amyloid-&#x3b2; fibrils in vitro and compact plaques in situ. J. Biol. Chem 281, 24566&#x2013;24574 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16787929</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor JP &amp; Strickland S Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost 93, 655&#x2013;660 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383744</ArticleId><ArticleId IdType="pubmed">15841309</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto N et al. Leptin inhibits amyloid beta-protein degradation through decrease of neprilysin expression in primary cultured astrocytes. Biochem. Biophys. Res. Commun 445, 214&#x2013;217 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24508800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY &amp; Landreth GE The role of microglia in amyloid clearance from the AD brain. J. Neural Transm 117, 949&#x2013;960 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Loria F et al. &#x3b1;-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol. 134, 789&#x2013;808 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28725967</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova N et al. Toll-like receptor 4 promotes &#x3b1;-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol 179, 954&#x2013;963 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157205</ArticleId><ArticleId IdType="pubmed">21801874</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner L et al. Toll-like receptor 4 is required for &#x3b1;-synuclein dependent activation of microglia and astroglia. Glia 61, 349&#x2013;360 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568908</ArticleId><ArticleId IdType="pubmed">23108585</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller EJ, Brooks MM, Golde TE, Giasson BI &amp; Chakrabarty P Inflammatory pre-conditioning restricts the seeded induction of &#x3b1;-synuclein pathology in wild type mice. Mol. Neurodegener 12, 1 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210310</ArticleId><ArticleId IdType="pubmed">28049533</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Paik SR, Jou I &amp; Park SM Microglial phagocytosis is enhanced by monomeric &#x3b1;-synuclein, not aggregated &#x3b1;-synuclein: implications for Parkinson&#x2019;s disease. Glia 56, 1215&#x2013;1223 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18449945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M &amp; Trojanowski JQ Neurodegenerative tauopathies. Annu. Rev. Neurosci 24, 1121&#x2013;1159 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR &amp; Lees AJ Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8, 270&#x2013;279 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19233037</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S et al. Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. J. Exp. Med 217, e20190783 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041709</ArticleId><ArticleId IdType="pubmed">31826239</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer&#x2019;s disease. Nature 552, 355&#x2013;361 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaliere F et al. In vitro &#x3b1;-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol. Dis 103, 101&#x2013;112 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28411117</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE Harnessing immunoproteostasis to treat neurodegenerative disorders. Neuron 101, 1003&#x2013;1015 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594693</ArticleId><ArticleId IdType="pubmed">30897353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L &amp; El Khoury J Microglia in neurodegeneration. Nat. Neurosci 21, 1359&#x2013;1369 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM &amp; Colonna M The identity and function of microglia in neurodegeneration. Nat. Immunol 19, 1048&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832&#x2013;1840 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Greggio E et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis 23, 329&#x2013;341 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16750377</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x2019;s disease: a case-control study. Lancet Neurol. 7, 583&#x2013;590 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med 4, 164ra161 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23241745</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M et al. Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, e12813 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB et al. Parkinson&#x2019;s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842&#x2013;16847 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283829</ArticleId><ArticleId IdType="pubmed">16269541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ et al. LRRK2 kinase regulates alpha-synuclein propagation via RAB35 phosphorylation. Nat. Commun 9, 3465 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110743</ArticleId><ArticleId IdType="pubmed">30150626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao HT et al. LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson&#x2019;s disease mouse model. Mol. Ther. Nucleic Acids 8, 508&#x2013;519 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573879</ArticleId><ArticleId IdType="pubmed">28918051</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson MX, Peng C, Trojanowski JQ &amp; Lee VMY LRRK2 activity does not dramatically alter &#x3b1;-synuclein pathology in primary neurons. Acta Neuropathol. Commun 6, 45 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984465</ArticleId><ArticleId IdType="pubmed">29855356</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA et al. G2019S-LRRK2 expression augments &#x3b1;-synuclein sequestration into inclusions in neurons. J. Neurosci 36, 7415&#x2013;7427 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945663</ArticleId><ArticleId IdType="pubmed">27413152</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med 24, 1910&#x2013;1918 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL Lewy bodies in Alzheimer&#x2019;s disease: a neuropathological review of 145 cases using &#x3b1;-synuclein immunohistochemistry. Brain Pathol. 10, 378&#x2013;384 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol 72, 587&#x2013;598 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J. Neurosci 36, 7364&#x2013;7374 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA &amp; Higgins GA Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J &amp; Selkoe DJ The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 9, 119&#x2013;128 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T et al. Induction of tau pathology by intracerebral infusion of amyloid-&#x3b2;-containing brain extract and by amyloid-&#x3b2; deposition in APP &#xd7; Tau transgenic mice. Am. J. Pathol 171, 2012&#x2013;2020 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111123</ArticleId><ArticleId IdType="pubmed">18055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos B et al. Heterotypic seeding of Tau fibrillization by pre-aggregated A&#x3b2; provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Acta Neuropathol. 131, 549&#x2013;569 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789256</ArticleId><ArticleId IdType="pubmed">26739002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J &amp; Nitsch RM Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A&#x3b2;42 fibrils. Science 293, 1491&#x2013;1495 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes LA et al. A&#x3b2;-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol. 138, 913&#x2013;941 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31414210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487&#x2013;1491 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med 24, 29&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636&#x2013;640 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa T et al. &#x3b1;-synuclein fibrils exhibit gain of toxic function, promoting tau aggregation and inhibiting microtubule assembly. J. Biol. Chem 291, 15046&#x2013;15056 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946922</ArticleId><ArticleId IdType="pubmed">27226637</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggerty T et al. Hyperphosphorylated Tau in an &#x3b1;-synuclein-overexpressing transgenic model of Parkinson&#x2019;s disease. Eur. J. Neurosci 33, 1598&#x2013;1610 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086951</ArticleId><ArticleId IdType="pubmed">21453448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills J et al. Tauopathic changes in the striatum of A53T &#x3b1;-synuclein mutant mouse model of Parkinson&#x2019;s disease. PLoS One 6, e17953 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061878</ArticleId><ArticleId IdType="pubmed">21445308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Takahashi R, Ikeda T &amp; Yamada M Cross-seeding effects of amyloid &#x3b2;-protein and &#x3b1;-synuclein. J. Neurochem 122, 883&#x2013;890 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22734715</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ &amp; LaFerla FM Synergistic interactions between A&#x3b2;, tau, and &#x3b1;-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci 30, 7281&#x2013;7289 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E et al. &#x3b2;-amyloid peptides enhance &#x3b1;-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. Proc. Natl Acad. Sci. USA 98, 12245&#x2013;12250 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59799</ArticleId><ArticleId IdType="pubmed">11572944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassil F et al. Amyloid-beta (A&#x3b2;) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with A&#x3b2; pathology. Neuron 105, 260&#x2013;275 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6981053</ArticleId><ArticleId IdType="pubmed">31759806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachhuber T et al. Inhibition of amyloid-&#x3b2; plaque formation by &#x3b1;-synuclein. Nat. Med 21, 802&#x2013;807 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26099047</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B et al. Anti-&#x3b1;-synuclein immunotherapy reduces &#x3b1;-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol. Commun 5, 7 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237270</ArticleId><ArticleId IdType="pubmed">28086964</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E et al. Passive immunization reduces behavioral and neuropathological deficits in an &#x3b1;-synuclein transgenic model of Lewy body disease. PLoS One 6, e19338 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D et al. Reducing C-terminal-truncated &#x3b1;-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson&#x2019;s disease-like models. J. Neurosci 34, 9441&#x2013;9454 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087215</ArticleId><ArticleId IdType="pubmed">25009275</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran HT et al. &#x3b1;-synuclein immunotherapy blocks uptake and templated propagation of misfolded &#x3b1;-synuclein and neurodegeneration. Cell Rep. 7, 2054&#x2013;2065 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410967</ArticleId><ArticleId IdType="pubmed">24931606</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobuhara CK et al. Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am. J. Pathol 187, 1399&#x2013;1412 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455060</ArticleId><ArticleId IdType="pubmed">28408124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ et al. Antibody-aided clearance of extracellular &#x3b1;-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci 32, 13454&#x2013;13469 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752153</ArticleId><ArticleId IdType="pubmed">23015436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandler M et al. Active immunization against &#x3b1;-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol. Neurodegener 10, 10 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411775</ArticleId><ArticleId IdType="pubmed">25886309</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E et al. Effects of &#x3b1;-synuclein immunization in a mouse model of Parkinson&#x2019;s disease. Neuron 46, 857&#x2013;868 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandler M et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson&#x2019;s disease clinical trials. Acta Neuropathol. 127, 861&#x2013;879 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034750</ArticleId><ArticleId IdType="pubmed">24525765</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR &amp; Pulst SM Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 15, 707&#x2013;714 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152438</ArticleId><ArticleId IdType="pubmed">29560813</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M et al. Development of a biochemical diagnosis of Parkinson disease by detection of &#x3b1;-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163&#x2013;172 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27918765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus A et al. Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol. 137, 585&#x2013;598 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426988</ArticleId><ArticleId IdType="pubmed">30570675</ArticleId></ArticleIdList></Reference><Reference><Citation>Covell DJ et al. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson&#x2019;s disease. Neuropathol. Appl. Neurobiol 43, 604&#x2013;620 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5632188</ArticleId><ArticleId IdType="pubmed">28386933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons GS et al. Detection of Alzheimer disease (AD)-specific tau pathology in AD and nonAD tauopathies by immunohistochemistry with novel conformation-selective tau antibodies. J. Neuropathol. Exp. Neurol 77, 216&#x2013;228 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251598</ArticleId><ArticleId IdType="pubmed">29415231</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC et al. Exogenous &#x3b1;-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051&#x2013;20056 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL &amp; Diamond MI Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem 284, 12845&#x2013;12852 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J. Neurosci 33, 1024&#x2013;1037 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl Acad. Sci. USA 111, E4376&#x2013;E4385 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS et al. Multiple factors contribute to the peripheral induction of cerebral &#x3b2;-amyloidosis. J. Neurosci 34, 10264&#x2013;10273 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608275</ArticleId><ArticleId IdType="pubmed">25080588</ArticleId></ArticleIdList></Reference><Reference><Citation>Burwinkel M, Lutzenberger M, Heppner FL, Schulz-Schaeffer W &amp; Baier M Intravenous injection of &#x3b2;-amyloid seeds promotes cerebral amyloid angiopathy (CAA). Acta Neuropathol. Commun 6, 23 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836327</ArticleId><ArticleId IdType="pubmed">29506560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92, 796&#x2013;812 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267&#x2013;280 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>